News and Announcements
Dimerix Reports Successful Phase 2a Trial of DMX-200, with 36% reduction in proteinuria in patients with Diabetic Nephropathy
- Published December 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phase 2a clinical trial for lead program DMX-200 was successfully completed.
- Data from this study met primary safety endpoint, with encouraging efficacy signals.
- Addition of Non-Executive Director Mr Hugh Alsop and Head of Drug Development Dr Robert Shepherd to the team.
- Share consolidation completed.
The successful completion of the Phase 2a clinical trial for our lead program, DMX-200, in Chronic Kidney Disease was the unequivocal highlight of the year. Not only did the data from this study meet the important primary endpoint of safety, the exciting and unexpected observation was that a statistically significant efficacy response was seen in the subgroup of patients with diabetic nephropathy. These clinical outcomes significantly enhance the underlying value proposition for DMX-200.
The year has also seen us bolster our team, complete a share consolidation and start marketing our trial data to pharmaceutical partners and investors on the world stage.
About Dimerix Limited (ASX: DXB)
Dimerix Limited (ASX: DXB) is a clinical-stage drug development company with our lead program DMX-200, currently in Phase II clinical trials for Chronic Kidney Disease (CKD).
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
